NEW YORK, Sept. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

NEW YORK, Aug. 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=98706&from=4 CLASS PERIOD: January 18, 2023 to June 25, ...

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Moderna, Inc. (NASDAQ: MRNA) securities between January 18, 2023 and June 25, 2024. Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA ("mRNA") therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular dise ...

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Moderna investors who were adversely affected by alleged securities fraud between January 18, 2023 and June 25, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moderna-lawsuit-submission-form ...

文章核心观点 - 根据分析师的最新评级,Moderna公司的股票存在5.30%的上涨空间[1] - 分析师给出的Moderna公司的目标价格区间为80美元至304美元不等[1] 行业分析 - 根据最近3家分析师的评级,Moderna公司的平均目标价格为83.33美元[1] - 分析师对Moderna公司的评级包括买入、持有和卖出等[16][21] 公司分析 - Moderna公司目前有25家分析师跟踪评级[1] - 分析师给出的最高目标价为304美元,最低目标价为80美元[1]

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. Start slideshow: 10 Oversold Stocks You Should Know About » In trading on Tuesday, shares of Moderna entered into overs ...

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=98139&from=3 CLASS PERIOD: January 18, 2023 to June ...

SAN DIEGO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of purchasers or acquirers of Moderna, Inc. (NASDAQ: MRNA) ("Moderna" or the "Company") securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), charging the Company and certain senior executives (collectively, "Defendants") with violations of the federal securities laws. Moderna investors have until October 8, 2024 to seek appointment as lead plaintiff of the Moderna class action lawsu ...

akinbostanci Introduction Moderna, Inc.'s (NASDAQ:MRNA) stock has been sluggish this past year, returning -27%. In fact, Moderna was reportedly the "most shorted S&P 500 healthcare stock in July." My last analysis focused on the company's prospects, with their COVID-19/influenza combination vaccine targeting an $8 billion-plus market. My January analysis maintained a long-term perspective, culminating in a "strong buy" recommendation, noting: The pandemic-induced revenues only scratched the surface of Moder ...